1. Home
  2. ACRS vs SHMD Comparison

ACRS vs SHMD Comparison

Compare ACRS & SHMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

N/A

Current Price

$3.06

Market Cap

230.8M

Sector

Health Care

ML Signal

N/A

Logo SCHMID Group N.V. Class A Ordinary Shares

SHMD

SCHMID Group N.V. Class A Ordinary Shares

N/A

Current Price

$4.47

Market Cap

209.7M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ACRS
SHMD
Founded
2012
1864
Country
United States
Germany
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
230.8M
209.7M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
ACRS
SHMD
Price
$3.06
$4.47
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$9.75
N/A
AVG Volume (30 Days)
1.2M
168.0K
Earning Date
11-06-2025
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$15,742,000.00
$85,165,542.00
Revenue This Year
N/A
N/A
Revenue Next Year
$6.06
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.05
$1.86
52 Week High
$3.48
$6.70

Technical Indicators

Market Signals
Indicator
ACRS
SHMD
Relative Strength Index (RSI) 56.89 47.15
Support Level $3.12 $4.39
Resistance Level $3.48 $5.47
Average True Range (ATR) 0.22 0.66
MACD -0.00 -0.04
Stochastic Oscillator 52.54 35.63

Price Performance

Historical Comparison
ACRS
SHMD

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

About SHMD SCHMID Group N.V. Class A Ordinary Shares

Schmid Group NV is a global supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).

Share on Social Networks: